CASI PHARMACEUTICALS, INC.: 10-Q filed 2013-08-14

Name: CASI PHARMACEUTICALS, INC.: 10-Q filed 2013-08-14
Creator: CASI PHARMACEUTICALS, INC.

What CASI PHARMACEUTICALS, INC. reported in its quarterly report filed 2013-08-14 (fiscal Q2 2013): 25 published measures, 60 facts as tagged in accession 0001144204-13-045481.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-08-14
Fiscal period: fiscal Q2 2013
Accession: 0001144204-13-045481 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CASI PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-06-30	17,538,601	USD
At 2012-12-31	8,977,995	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2013-06-30	16,788,868	USD
At 2012-12-31	8,235,242	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-06-30	17,222,918	USD
At 2012-12-31	8,049,237	USD
At 2012-06-30	10,058,935	USD
At 2011-12-31	1,080,630	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-1,851,840	USD	91
2013-01-01 to 2013-06-30	-2,987,727	USD	181
2012-04-01 to 2012-06-30	-10,463,218	USD	91
2012-01-01 to 2012-06-30	-12,997,076	USD	182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	-1,186,168	USD	181
2012-01-01 to 2012-06-30	-267,436	USD	182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	16,926	USD	181
2012-01-01 to 2012-06-30	0	USD	182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	10,376,775	USD	181
2012-01-01 to 2012-06-30	9,245,741	USD	182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	-16,926	USD	181
2012-01-01 to 2012-06-30	0	USD	182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2013-06-30	-396,318,974	USD
At 2012-12-31	-393,331,247	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2013-06-30	60,445	USD
At 2012-12-31	52,556	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	1,164,578	USD	181
2012-01-01 to 2012-06-30	468,353	USD	182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-06-30	17,456,866	USD
At 2012-12-31	8,908,012	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-06-30	749,733	USD
At 2012-12-31	742,753	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-06-30	599,007	USD
At 2012-12-31	504,851	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2013-06-30	0	USD
At 2012-12-31	669,310	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	836,582	USD	91
2013-01-01 to 2013-06-30	1,342,957	USD	181
2012-04-01 to 2012-06-30	696,287	USD	91
2012-01-01 to 2012-06-30	1,257,536	USD	182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-06-30	27,102,583	shares
At 2012-12-31	22,582,938	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-06-30	420,871,062	USD
At 2012-12-31	409,374,905	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2013-06-30	21,290	USD
At 2012-12-31	17,427	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2013-06-30	150,726	USD
At 2012-12-31	151,219	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2013-06-30	233,948	USD
At 2012-12-31	189,465	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-1,851,840	USD	91
2013-01-01 to 2013-06-30	-2,987,727	USD	181
2012-04-01 to 2012-06-30	-10,546,968	USD	91
2012-01-01 to 2012-06-30	-13,332,076	USD	182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	1,015,701	USD	91
2013-01-01 to 2013-06-30	1,645,603	USD	181
2012-04-01 to 2012-06-30	601,502	USD	91
2012-01-01 to 2012-06-30	1,698,248	USD	182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	-669,310	USD	181
2012-01-01 to 2012-06-30	-1,932,742	USD	182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	94,156	USD	181
2012-01-01 to 2012-06-30	123,555	USD	182

Inspect the source

Entity: CASI PHARMACEUTICALS, INC. / CIK 0000895051
Captured: 2026-09-22 19:33 UTC
SEC response SHA-256: a5465bb63979ec441cdd2d0b7761265dc0541f5ee25dcdffded348a960f99c09

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000895051.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))